Children's Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology

儿童慈善医院儿科药理学合作奖学金计划

• 批准号: 10409568
• 负责人: Jennifer Lynn Goldman
• 金额: $ 17.31万
• 依托单位: CHILDREN'S MERCY HOSP (KANSAS CITY, MO)
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2026-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10409568
• 关键词: Child; Fellowship Program; Hospitals; pediatric pharmacology

Abstract The Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation at Children’s Mercy Hospital (CMH) in Kansas City, offers one of the largest, most diverse, Pediatric Clinical Pharmacology post-doctoral training programs in the U.S. It is constituted by 20 faculty including 1) clinicians cross-trained in Allergy/ Asthma/Immunology, Behavioral Medicine, Cardiology, Environmental/Occupational Health, Gastroenterology, Hematology/Oncology, Infectious Diseases, Maternal/Fetal Medicine, Neonatology, Nephrology, Nursing, Pharmacy, Rehabilitation Medicine, and Toxicology, along with 2) basic/translational scientists with experience in analytical chemistry, genetics, genomics, in vitro biotransformation, and molecular biology. Affiliated faculty contribute additional expertise in the areas of Bioethics, Bioinformatics, Health Outcomes, and Pharmaco- epidemiology. The program has made substantial contributions in the areas of pharmacogenetics, pharmaco- metrics, and early phase clinical trial design. The program combines robust didactic and experiential training in pharmacogenetics/genomics, metabolomics, pharmacometrics, pharmacoepidemiology, drug development, and the responsible conduct of research. It also offers unique elective opportunities dedicated to pediatric PBPK-based modeling and simulation (Simcyp/Certara), pediatric regulatory review and approval (FDA), bioinformatics (PharmGKB), Formulary management (CMH/Medicaid), and adult pharmacology (Mayo). Two independent Masters programs offered by affiliated medical schools round out the academic program at CMH. All teaching is accomplished by faculty with significant research experience in their respective subject areas. Trainees affiliate with the program for a minimum of three years; the first two years in Clinical Pharmacology are blended with the second and third years of their subspecialty training and their third year is dedicated to clinical pharmacology. Under the direction of a junior mentor, a senior mentor, and a scholarship oversight committee, fellows complete both a clinical and translational research project, produce several publications/ presentations, compete for a minimum of one research grant, and develop a plan to transition to independence prior to graduation. Quality is continually assured by a robust evaluation strategy and diversity is supported by a comprehensive recruitment strategy. Since its inception, the program at CMH has trained 24 pediatric clinical pharmacology fellows (17 pediatricians, 6 pharmacists, 1 nurse; 14 female, 2 African American, 1 Hispanic, 1 Native-American, 3 Asian) who during their fellowship period have collectively delivered 118 scientific presentations, prepared 102 peer-reviewed manuscripts and successfully competed for over $1,500,000 in intramural and extramural funding. The program is one of only three American Board of Clinical Pharmacology accredited training programs dedicated solely to Pediatric Clinical Pharmacology and its longstanding record of excellence provides applicants with unparalleled training in the discipline.

抽象的 儿童慈善医院临床药理学、毒理学和治疗创新科 （CMH）位于堪萨斯城，提供最大、最多样化的儿科临床药理学博士后之一 美国的培训计划 由 20 名教员组成，其中包括 1) 在过敏/过敏方面接受过交叉培训的信徒 哮喘/免疫学、行为医学、心脏病学、环境/职业健康、胃肠病学、 血液学/肿瘤学、传染病学、母婴医学、新生儿学、肾脏病学、护理学、 药学、康复医学和毒理学，以及 2) 名具有经验的基础/转化科学家 分析化学、遗传学、基因组学、体外生物转化和分子生物学。 在生物伦理学、生物信息学、健康结果和药理学领域贡献更多专业知识 该计划在药物遗传学、药物遗传学领域做出了重大贡献。 该计划结合了强有力的教学和体验式培训。 药物遗传学/基因组学、代谢组学、药理学、药物流行病学、药物开发、 以及负责任的研究行为还提供了专门针对儿科的独特选修机会。 基于 PBPK 的建模和仿真 (Simcyp/Certara)、儿科监管审查和批准 (FDA)、 生物信息学 (PharmGKB)、处方管理 (CMH/Medicaid) 和成人药理学 (Mayo) 两个。 附属医学院提供的独立硕士课程完善了 CMH 的学术课程。 所有教学均由在各自学科领域具有丰富研究经验的教师完成。 学员参加该计划至少三年；前两年学习临床药理学； 与他们的专业培训的第二年和第三年相结合，第三年致力于 临床药理学在初级导师、高级导师的指导下进行，并有学术监督。 委员会，研究员完成了临床和转化研究项目，出版了几篇出版物/ 演讲，竞争至少一项研究经费，并制定过渡到独立的计划 在毕业之前，质量将通过强有力的评估策略得到持续保证，并且多样性得到支持。 自启动以来，CMH 项目已培训了 24 名儿科临床人员。 药理学研究员（17 名儿科医生、6 名药剂师、1 名护士；14 名女性、2 名非裔美国人、1 名西班牙裔、1 名 美洲原住民，3 名亚洲人）在奖学金期间共发表了 118 项科学成果 演讲，准备了 102 份经过同行评审的手稿，并成功角逐超过 1,500,000 美元的奖金 该项目是美国临床药理学委员会仅有的三个项目之一。 专门针对儿科临床药理学及其长期记录的认可培训计划 卓越为申请者提供了无与伦比的学科培训。